AUTHOR=Chen Jianxin , Wang Junhui 

TITLE=Case report: ALK D1225N missense mutation in lung adenocarcinoma responds to tyrosine kinase inhibitors

JOURNAL=Frontiers in Pharmacology

VOLUME=14

YEAR=2023

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1190447

DOI=10.3389/fphar.2023.1190447

ISSN=1663-9812

ABSTRACT=<p><italic>ALK</italic> gene missense mutations are conventionally considered non-driver mutations without pathological significance, and therefore, there is a lack of effective target drugs against them. The standard treatment option for patients with <italic>ALK</italic> missense mutations is chemotherapy with or without antiangiogenic agents, which usually results in unsatisfactory outcomes. Herein, we present the case of a patient with metastatic lung adenocarcinoma harboring the only missense mutation in <italic>ALK</italic> D1225N responding to two ALK-tyrosine kinase inhibitors (TKIs), namely, crizotinib and ensartinib. Our case highlights that non-small cell lung cancer (NSCLC) patients harboring the D1225N mutation may benefit from ALK-TKIs, and therefore, ALK-TKIs should be considered candidates for further line treatment.</p>